Neither Loss of Bik Alone, nor Combined Loss of Bik and Noxa, Accelerate Murine Lymphoma Development or Render Lymphoma Cells Resistant to DNA Damaging Drugs
Overview
General Medicine
Authors
Affiliations
The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(-/-) nor Eμ-Myc/Bik(-/-)Noxa(-/-) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours.
Wu F, Zhang J, Jiang Q, Li Q, Li F, Li J Cell Cycle. 2024; 23(5):573-587.
PMID: 38701194 PMC: 11135814. DOI: 10.1080/15384101.2024.2348344.
Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Vitale I, Pietrocola F, Guilbaud E, Aaronson S, Abrams J, Adam D Cell Death Differ. 2023; 30(5):1097-1154.
PMID: 37100955 PMC: 10130819. DOI: 10.1038/s41418-023-01153-w.
Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
Winkler R, Piskor E, Kosan C Cells. 2023; 12(1).
PMID: 36611833 PMC: 9818924. DOI: 10.3390/cells12010037.
Targeting the Bcl-2 Family in B Cell Lymphoma.
Adams C, Clark-Garvey S, Porcu P, Eischen C Front Oncol. 2019; 8:636.
PMID: 30671383 PMC: 6331425. DOI: 10.3389/fonc.2018.00636.
Zhang L, Li X, Chao Y, He R, Liu J, Yuan Y Cell Commun Signal. 2018; 16(1):53.
PMID: 30176890 PMC: 6122640. DOI: 10.1186/s12964-018-0270-x.